前列腺特异性膜抗原正电子发射断层扫描靶向活检检测临床显著前列腺癌的诊断性能:系统评价与Meta分析
本系统评价与Meta分析纳入5项前瞻性研究共497例患者,评估PSMA-PET靶向活检检测临床显著前列腺癌的诊断准确性。PSMA-PET-TB的汇总敏感度、特异度、阳性预测值和阴性预测值分别为0.89、0.56、0.69和0.78;与MRI-TB联合时分别为0.91、0.64、0.75和0.85。作者认为PSMA-PET-TB诊断准确性良好,联合MRI似乎可改善,尤其在PI-RADS 3分病灶中有应用前景。
要点
- PSMA-PET靶向活检检测临床显著前列腺癌的汇总敏感度为0.89,特异度为0.56。
- PSMA-PET联合MRI靶向活检的汇总敏感度为0.91,特异度为0.64,阳性预测值0.75,阴性预测值0.85。
- PI-RADS 3分病灶中PSMA-PET靶向活检的敏感度0.69、特异度0.73、阳性预测值0.48、阴性预测值0.86。
核心结论
- PSMA-PET-TB对临床显著前列腺癌检测似乎具有良好诊断准确性,与MRI联合似乎可改善。
- 根据本Meta分析,PSMA-PET在临床显著前列腺癌检测中有前景,即在PI-RADS 3分病灶情况下。
- 需要进一步前瞻性研究探索基于PSMA-PET的诊断路径的真实临床效用。
研究设计与样本
- 系统评价与诊断性Meta分析,检索PubMed、Web of Science和Scopus(2021年12月)评估PSMA-PET-TB检测临床显著前列腺癌准确性的研究。
- 共纳入5项前瞻性研究,涉及497例患者。
主要发现
- PSMA-PET-TB检测临床显著前列腺癌的汇总敏感度0.89(95%CI 0.85-0.93)、特异度0.56(95%CI 0.29-0.80)、阳性预测值0.69(95%CI 0.58-0.79)、阴性预测值0.78(95%CI 0.50-0.93)。
- 评估PSMA-PET+MRI-TB策略的3项研究中,汇总敏感度0.91(95%CI 0.77-0.97)、特异度0.64(95%CI 0.40-0.82)、阳性预测值0.75(95%CI 0.56-0.87)、阴性预测值0.85(95%CI 0.62-0.95)。
- PI-RADS 3分病灶的敏感度0.69、特异度0.73、阳性预测值0.48、阴性预测值0.86。
关键数值与推荐
- PSMA-PET-TB检测临床显著前列腺癌的汇总敏感度0.89(95%CI 0.85-0.93)、特异度0.56(95%CI 0.29-0.80)、阳性预测值0.69(95%CI 0.58-0.79)、阴性预测值0.78(95%CI 0.50-0.93)。
- PSMA-PET+MRI-TB策略的汇总敏感度0.91(95%CI 0.77-0.97)、特异度0.64(95%CI 0.40-0.82)、阳性预测值0.75(95%CI 0.56-0.87)、阴性预测值0.85(95%CI 0.62-0.95)。
- PI-RADS 3分病灶的敏感度0.69、特异度0.73、阳性预测值0.48、阴性预测值0.86。
临床怎么用
- 作者认为PSMA-PET-TB对临床显著前列腺癌检测似乎具有良好诊断准确性,与MRI联合似乎可改善。
- 作者认为PSMA-PET在临床显著前列腺癌检测中有前景,即在PI-RADS 3分病灶情况下。
- 作者提出需要进一步前瞻性研究探索基于PSMA-PET的诊断路径的真实临床效用。
局限性
- 需要进一步前瞻性研究探索基于PSMA-PET的诊断路径的真实临床效用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Prostate-specific membrane antigen positron emission tomography (PSMA-PET) has gained acceptance as a staging tool for prostate cancer (PCa). Recent reports suggest an association between PSMA PET and detection of clinically significant PCa (csPCa) on prostate biopsy. OBJECTIVE: To assess the diagnostic accuracy of PSMA PET-targeted biopsy (PSMA-PET-TB) for csPCa detection. EVIDENCE ACQUISITION: We searched PubMed, Web of Science, and Scopus in December 2021 to identify studies assessing the accuracy of PSMA-PET-TB for csPCa detection. A diagnostic meta-analysis was performed to calculate pooled sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of PSMA-PET-TB alone and in combination with magnetic resonance imaging (MRI)-TB for detecting csPCa. EVIDENCE SYNTHESIS: Overall, five prospective studies involving 497 patients were eligible for this meta-analysis. For csPCa detection, PSMA-PET-TB had pooled sensitivity, specificity, PPV, and NPV of 0.89 (95% confidence interval [CI] 0.85-0.93), 0.56 (95% CI 0.29-0.80), 0.69 (95% CI 0.58-0.79), and 0.78 (95% CI 0.50-0.93), respectively. Among the three studies assessing the PSMA-PET + MRI-TB strategy, the pooled sensitivity, specificity, PPV, and NPV for csPCa detection were 0.91 (95% CI 0.77-0.97), 0.64 (95% CI 0.40-0.82), 0.75 (95% CI 0.56-0.87), and 0.85 (95% CI 0.62-0.95), respectively. For lesions with a Prostate Imaging-Reporting and Data System (PI-RADS) score of 3, the sensitivity, specificity, PPV, and NPV were 0.69, 0.73, 0.48, and 0.86, respectively. CONCLUSIONS: PSMA-PET-TB appears to have favorable diagnostic accuracy for csPCa detection and combination with MRI seems to improve this. According to our meta-analysis, PSMA-PET has promising clinical application for detection of csPCa, namely in the case of PI-RADS 3 lesions. Further prospective studies are needed to explore the true clinical utility of a PSMA-PET-based diagnostic pathway. PATIENT SUMMARY: Prostate-specific membrane antigen positron emission tomography (PSMA-PET) is a promising imaging method for detecting clinically significant prostate cancer and seems to have additional value to magnetic resonance imaging (MRI) for detection.
引用
- Kawada T, Yanagisawa T, Rajwa P, et al. Diagnostic Performance of Prostate-specific Membrane Antigen Positron Emission Tomography-targeted biopsy for Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol Oncol. 2022. PMID: 35715320. doi:10.1016/j.euo.2022.04.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。